azelnidipine

structure given in first source

Also Known As:

3-(1-diphenylmethylazetidin-3-yl)-5-isopropyl-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate; CS 905; CS-905; 3,5-Pyridinedicarboxylic acid, 2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-, 3-(1-(diphenylmethyl)-3-azetidinyl) 5-(1-methylethyl) ester, (+-)-

Networked: 128 relevant articles (24 outcomes, 45 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Shimada, Kazuyuki: 7 articles (03/2013 - 06/2007)
2.	Daida, Hiroyuki: 5 articles (01/2015 - 10/2009)
3.	Kario, Kazuomi: 5 articles (03/2013 - 06/2007)
4.	Sunagawa, Kenji: 5 articles (01/2012 - 09/2006)
5.	Miyauchi, Katsumi: 4 articles (01/2015 - 10/2009)
6.	Ito, Hiroshi: 4 articles (09/2014 - 10/2009)
7.	Hiramatsu, Katsutoshi: 4 articles (03/2013 - 01/2010)
8.	Ogihara, Toshio: 4 articles (08/2010 - 02/2004)
9.	Kuramoto, Kizuku: 4 articles (05/2010 - 08/2008)
10.	Horiuchi, Masatsugu: 4 articles (12/2006 - 02/2004)

Related Diseases

1.	Hypertension (High Blood Pressure) 12/01/1989 - "These effects of CS-905 on renal functions may be beneficial in the treatment of hypertension." 03/01/2013 - "These results suggest that azelnidipine improved morning hypertension with its sustained BP-lowering effect." 01/01/2015 - "Azelnidipine is effective and safe in the treatment of hypertension in Chinese patients." 12/01/2022 - "It suggests that the adoption of azelnidipine as the new gold standard CCB could help India battle its hypertension epidemic." 03/01/2013 - "We previously reported the results of the Azelnidipine Treatment for Hypertension Open-label Monitoring in the Early morning (At-HOME) Study, which indicated that azelnidipine effectively controlled morning hypertension. "
2.	Essential Hypertension 02/01/1999 - "A new Ca-antagonist, azelnidipine, reduced blood pressure during exercise without augmentation of sympathetic nervous system in essential hypertension: a randomized, double-blind, placebo-controlled trial." 01/01/2007 - "Clinical study with azelnidipine in patients with essential hypertension. " 01/01/2007 - "In this study, the antiarteriosclerotic and cardiac hypertrophy-inhibitory effects, and the autonomic nervous activity in essential hypertension of azelnidipine were investigated. " 10/01/2006 - "In this study, we compared the efficacy of azelnidipine to that of amlodipine in lowering morning BP and reducing PR in outpatients with essential hypertension. " 10/01/2006 - "Efficacy of azelnidipine on home blood pressure and pulse rate in patients with essential hypertension: comparison with amlodipine."
3.	Albuminuria 03/18/2013 - "The aim of this study was to compare the effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria. " 01/01/2015 - "Azelnidipine was more effective for controlling blood pressure than trichlormethiazide in Japanese type 2 diabetes patients, whereas trichlormethiazide was more effective for reducing albuminuria than azelnidipine. " 03/18/2013 - "Our results suggested that cilnidipine is more efficient in reducing albuminuria than azelnidipine independent of its blood pressure lowering effect in type 2 diabetic patients with hypertension. " 03/18/2013 - "Comparison of effects of cilnidipine and azelnidipine on blood pressure, heart rate and albuminuria in type 2 diabetics with hypertension: A pilot study." 07/01/2013 - "Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study."
4.	Insulin Resistance 01/01/2015 - "In this study, we evaluated the effects of azelnidipine, a calcium channel blocker, on ROS-mediated insulin resistance in adipocytes. " 01/01/2015 - "Recent studies have demonstrated that azelnidipine could improve insulin resistance and glucose tolerance by potentially inhibiting sympathetic nerve activity. " 12/01/2006 - "These results suggest that azelnidipine improved glucose intolerance mainly through inhibition of oxidative stress and enhanced the inhibitory effects of olmesartan on glucose intolerance, as well as the clinical possibility that the combination of CCB and ARB could be more effective than monotherapy in the treatment of insulin resistance." 09/10/2011 - "These results suggest that azelnidipine treatment may have beneficial effects on glucose tolerance, insulin sensitivity, the inflammatory state, and number of circulating progenitor cells in non-diabetic patients with essential hypertension." 09/10/2011 - "However, it remains unclear if long-acting calcium channel blockers (CCBs) such as azelnidipine and amlodipine affect glucose tolerance and insulin resistance in clinical practice. "
5.	Inflammation (Inflammations) 01/01/2010 - "We examined whether a new CCB (azelnidipine) could influence the inflammatory response of human peripheral blood mononuclear cells (PBMCs), which are recruited to inflammatory lesions and modulate inflammation. " 12/15/2006 - "These findings imply a protective role of azelnidipine against inflammation in atherosclerosis." 10/01/2014 - "In the present study, we examined the efficacy of olmesartan and azelnidipine monotherapy (2 mg/kg or 10 mg/kg each) and their combination therapy (1 mg/kg each) on stroke-prone spontaneously hypertensive rats (SHR-SP) in relation to oxidative stress, inflammation, and the neurovascular unit. " 11/01/2009 - "It is suggested that the combination of olmesartan and azelnidipine has advantages over the combination of olmesartan and a thiazide with respect to avoiding hyperuricemia, sympathetic activation, renin-angiotensin-aldosterone system stimulation, inflammation, oxidative stress, and increased arterial stiffness in patients with moderate hypertension. " 04/01/2011 - "The adjusted percent reduction in UACR in the olmesartan/HCTZ group was significantly greater than that in the olmesartan/azelnidipine group (-43.2 vs. -24.0%, P = 0.0014), although the olmesartan/azelnidipine group showed greater decreases in central systolic BP (SBP; P = 0.04), oxidative stress (urinary 8-isoprostane; P = 0.02), inflammation (high-sensitivity C-reactive protein; P = 0.04), and insulin resistance (the homeostasis model assessment insulin resistance index (HOMA(IR)); P < 0.001) than the olmesartan/HCTZ group. "

Related Drugs and Biologics

1.	Amlodipine (Norvasc)
2.	olmesartan
3.	Calcium Channel Blockers (Blockers, Calcium Channel)
4.	1,4-dihydropyridine (dihydropyridine)
5.	Antihypertensive Agents (Antihypertensives)
6.	Angiotensin Receptor Antagonists
7.	Olmesartan Medoxomil (Votum)
8.	Trichlormethiazide (Naqua)
9.	Diuretics
10.	Nifedipine (Adalat)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Intravenous Administration
4.	Stents
5.	Peritoneal Dialysis